Keyphrases
Percutaneous Coronary Intervention
69%
Acute Coronary Syndrome
67%
Heart Failure
62%
Meta-analysis
60%
ST-elevation Myocardial Infarction (STEMI)
60%
Confidence Interval
60%
Systematic Meta-analysis
40%
Myocardial Infarction
38%
Patients with Heart Failure
29%
All-cause Mortality
26%
Randomized Controlled Trial
26%
Meta-analysis of Randomized Controlled Trials
23%
Left Ventricular Assist Device
23%
Myocardial Bridging
23%
Revascularization
23%
Myocardial Infarction Patients
20%
Optical Coherence Tomography
19%
Ejection Fraction
18%
Acute Myocardial Infarction
18%
Fractional Flow Reserve
18%
Cardiomyogenesis
18%
Dapagliflozin
18%
Edoxaban
18%
Percutaneous Endoscopic Gastrostomy
18%
Impella
18%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
18%
Stent Thrombosis
18%
Risk Ratio
18%
Bleeding
17%
Myocardium
17%
Atrial Fibrillation
17%
Left Ventricular Function
17%
Microvascular Obstruction
17%
Antithrombotic Therapy
17%
Primary Percutaneous Coronary Intervention
16%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
Heart Failure Hospitalization
16%
Myocytes
16%
Major Adverse Cardiovascular Events
15%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
15%
Hazard Ratio
15%
Heart Failure Patients
14%
Cardiomyocytes
14%
Randomized Trial
14%
Coronary Microvascular Obstruction
14%
Left Ventricular Ejection Fraction
14%
Clinical Outcomes
14%
Non-obstructive Coronary Artery Disease
14%
Duchenne muscular Dystrophy
14%
Type 2 Diabetic Patients
14%
Medicine and Dentistry
Congestive Heart Failure
92%
Meta-Analysis
67%
Percutaneous Coronary Intervention
65%
Acute Coronary Syndrome
52%
ST Segment Elevation Myocardial Infarction
46%
Myocardial Infarction
42%
Systematic Review
41%
Cardiovascular System
37%
Heart Muscle Ischemia
29%
Randomized Controlled Trial
27%
Coronary Artery Disease
26%
Revascularization
25%
Cardiovascular Disease
24%
Obstruction
24%
Coronary Artery
24%
Optical Coherence Tomography
23%
Progenitor Cell
23%
Fractional Flow Reserve
23%
Left Ventricular Assist Device
23%
Myocardial Bridge
23%
Bleeding
21%
Disease
20%
Dapagliflozin
18%
Antiplatelet
18%
Cardiac Muscle Cell
18%
Stent Thrombosis
15%
Diagnosis
15%
Ejection Fraction
15%
Primary Percutaneous Coronary Intervention
15%
Drug-Eluting Stent
15%
Myocardial Disease
14%
Antithrombotic Therapy
14%
Acute Heart Infarction
14%
Heart Left Atrium Pressure
14%
Myocardium
13%
Angina pectoris
13%
Placebo
13%
Clinical Trial
13%
Infarction
12%
Dystrophin
12%
Personalized Medicine
12%
Heart Left Ventricle Function
12%
Heart Ventricle Arrhythmia
12%
Atrial Fibrillation
11%
Cardiac Magnetic Resonance Imaging
11%
Combination Therapy
11%
Duchenne Muscular Dystrophy
11%
Sodium Glucose Cotransporter 2 Inhibitor
11%
Heart Ventricle Remodeling
11%
Recurrent Disease
11%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Heart Infarction
49%
Acute Coronary Syndrome
47%
Randomized Controlled Trial
37%
Disease
28%
Bleeding
26%
ST Segment Elevation Myocardial Infarction
23%
Cardiovascular Disease
21%
Coronary Artery Disease
20%
All Cause Mortality
19%
Sodium Glucose Cotransporter 2 Inhibitor
18%
Dapagliflozin
18%
Non Insulin Dependent Diabetes Mellitus
18%
Acute Heart Infarction
18%
Heart Muscle Ischemia
17%
Ischemic Heart Disease
17%
Antiplatelet
17%
Edoxaban
17%
Inflammation
17%
Anticoagulant Agent
17%
Placebo
17%
Heart Ventricle Arrhythmia
16%
Obstruction
15%
Atrial Fibrillation
14%
Clinical Trial
14%
Antithrombotic Therapy
14%
Myocardial Bridging
14%
Biological Marker
12%
Myocardial Disease
11%
Comorbidity
11%
Heart Ventricle Remodeling
11%
Direct Oral Anticoagulant
10%
Heart Failure with Reduced Ejection Fraction
10%
Immunosuppressive Agent
10%
Coronary Artery Atherosclerosis
10%
Infarction
10%
Duchenne Muscular Dystrophy
9%
Chronic Graft Rejection
9%
Congestive Cardiomyopathy
9%
Heart Right Ventricle Failure
9%
Aortic Regurgitation
9%
Scar Formation
9%
Stent Thrombosis
9%
Syndrome
8%
Thromboembolism
8%
Dystrophin
8%
Cause of Death
7%
Pathophysiology
7%
Heart Disease
7%
Diabetes Mellitus
7%